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 2 
Purpose: Treatments for breast cancer can lead to chronic musculoskeletal problems. This 3 
study aimed to systematically review the evidence surrounding the cost-effectiveness of 4 
exercise and physiotherapy interventions aimed at reducing the risk of physical symptoms 5 
and functional limitations due to breast cancer treatment.  6 
 7 
Methods: A systematic review of the cost-effectiveness of exercise and physiotherapy 8 
interventions during and following treatment for breast cancer was undertaken according to 9 
PRISMA guidelines. Literature searches were carried out in Ovid MEDLINE, Ovid Embase, 10 
Web of Science, EconLit, CINAHL, PsycINFO, Scopus and the Cochrane Library. Cost-11 
effectiveness evidence was summarised in a descriptive manner and studies were assessed 12 
using quality appraisal tools. The review protocol was registered on PROSPERO.  13 
 14 
Results: A total of 7,783 articles were identified and seven were included in the final review. 15 
Five studies undertook trial-based economic evaluations whereas two studies conducted 16 
economic evaluation based on decision models. One study was a cost-effectiveness analysis 17 
(CEA), three undertook stand-alone cost-utility analyses (CUA) and three studies were 18 
combined CEAs and CUAs. Three studies reported favourable cost-effectiveness results for 19 
different exercise or physiotherapy interventions. In contrast, four studies found that exercise 20 
and physiotherapy interventions were not cost-effective on the basis of quality-adjusted life 21 
year outcomes. 22 
 23 
Conclusions: The evidence surrounding the cost-effectiveness of exercise and physiotherapy 24 
interventions for the treatment of breast cancer remains sparse with contrasting conclusions. 25 
Future research should particularly aim to broaden the evidence base by disentangling the 26 
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contributing effects of frequency, intensity, time and type of exercise and physiotherapy 27 
interventions on cost-effectiveness outcomes. 28 
 29 
 30 
Key Words 31 
Exercise, Rehabilitation, Cost-effectiveness, Systematic review, Economic Evaluation 32 
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INTRODUCTION 
 
Breast cancer is the most common form of cancer amongst women in the United Kingdom 
(UK) with approximately 50,000 new cases diagnosed each year [1]. Most women diagnosed 
with breast cancer have surgery to the breast and axilla, with many also requiring 
radiotherapy and chemotherapy [2,3]. These treatments can affect the muscles, nerves and 
lymphatic vessels in the shoulder and upper body, resulting in musculoskeletal problems such 
as limited range of motion, weakness, persistent pain, altered sensations and lymphoedema 
[4,5]. Studies suggest that between 10% and 64% of women have symptoms in their arm or 
shoulder up to three years after treatment [6]. These persistent symptoms can delay recovery, 
limit daily activities, and impair health-related quality of life (HRQoL). It is important that 
the UK National Health Service (NHS) and health systems in other countries provide 
adequate care for women to ensure recovery and return to usual activities after cancer 
treatment. 
 
Exercise interventions may alleviate the side-effects of cancer treatment with several 
systematic reviews of the literature suggesting they may be clinically effective [7-10]. 
McNeely et al.[8], for example, reported that exercise improves HRQoL and physical 
capacity and reduces fatigue in breast cancer patients. Furthermore, physical activity can 
improve cardiorespiratory capacity and well-being in cancer patients [9].  
 
Although exercise interventions have been shown to be clinically effective in several studies, 
information on their cost-effectiveness is sparse. Two systematic reviews, one investigating 
the cost-effectiveness of exercise-based interventions in the treatment of various chronic 
diseases [11] and the other the cost-effectiveness of cancer rehabilitation [10], identified only 
two economic evaluations of physical activity interventions for breast cancer patients [12,13]. 
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The first study reported that a home-based self-managed physiotherapy intervention and a 
supervised group-based exercise intervention with psychosocial support were more cost-
effective than usual care [12]. In contrast, the second study concluded that a home-based self-
managed exercise intervention was not cost-effective compared to an active control 
consisting of flexibility and relaxation activities after breast cancer surgery [13].  
 
Given limited resources in public health systems, healthcare interventions should seek to 
maximise health benefits or broader measures of social welfare with the resources available. 
To achieve efficient resource allocation, only methods of proven cost-effectiveness should be 
adopted for routine use in the NHS and other publicly-funded health systems [14-17]. 
Therefore, the aim of this study was to systematically review evidence on the cost-
effectiveness of exercise and physiotherapy interventions for the treatment of breast cancer to 
inform policy decisions in this clinical area.  
 
METHODS 
 
A systematic review of the literature, following Preferred Reporting Items for Systematic 
Review and Meta-Analyses (PRISMA) guidelines [18], on the cost-effectiveness of exercise 
and physiotherapy during and following treatment for breast cancer was undertaken. Literature 
searches were carried out in Ovid MEDLINE, PubMed, Ovid Embase, Web of Science, 
EconLit, CINAHL, PsycINFO, Scopus and The Cochrane Library (including the NHS 
Economic Evaluation Database (NHSEED) electronic databases with time horizons covering 
inception of the databases to 24th September 2018. Biomedical databases were searched using 
various combinations of keywords and medical subject headings (MeSH) based on terms 
relevant to breast cancer, physiotherapy, exercise or physical activity and economic evaluation. 
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Further details on the search strategies applied to each database are available in the Online 
Resource 1. Searches were not limited by date of publication or language. The review protocol 
was registered on PROSPERO (CRD42018108978).  
 
Selection criteria 
Economic evaluations of exercise and physiotherapy interventions for breast cancer patients 
were considered. Eligible types of economic evaluations included cost-effectiveness analyses, 
cost-benefit analyses, cost-utility analyses, cost consequences analyses, and cost-
minimisation analyses.  Each study was required to have reported both costs and 
consequences and compared an experimental intervention to at least one other intervention or 
control. Participants included in the selected studies were adults with a confirmed breast 
cancer diagnosis who were undergoing or had received treatment, including any surgical 
removal of breast tumour, e.g. mastectomy (simple, modified or radical), local wide excision 
or lumpectomy and/or axillary surgery (lymph node dissection/clearance or sentinel lymph 
node biopsy (SNB/SNLB) or dissection.  An exercise or physiotherapy intervention was 
defined as one that included an exercise intervention delivered and supported or unsupported 
by a physiotherapist or other health professional. Comparators included usual care/control, 
different types of exercises or no exercise. Descriptions of usual care/control were extracted 
from primary reports. Outcome measures included measures of cost-effectiveness, e.g. an 
incremental cost-effectiveness ratio (ICER) or a measure of net monetary benefit (NMB). All 
identified titles and abstracts were screened independently by two authors (KK and BM) and, 
where relevant, full text articles were obtained and assessed against the study inclusion 
criteria. Disagreements at each stage (title and abstract stage, full report stage) were resolved 
by discussion or referred to a third author (SP) for final assessment. 
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Data Extraction 
Data extraction was carried out by one reviewer (KK) and checked by a second reviewer 
(BM). Any disagreements were resolved through discussion or through a final assessment by 
a third reviewer (SP). Data were extracted using a standardised form. Extracted data items 
included: author(s), year of publication, country and setting, patient characteristics, 
intervention and comparator details, main analytical approaches (e.g. patient-level analysis or 
decision-analytic modelling) and the primary outcome(s) specified for the economic analysis. 
In addition, details of estimation and adjustment for HRQoL, key assumptions made in the 
base case or tested in sensitivity analyses, direct costs (medical and non-medical) and 
productivity costs estimated, estimates of cost-effectiveness, and approaches to quantifying 
uncertainty (e.g. decision uncertainty to address uncertainty around the value of the cost-
effectiveness threshold, probabilistic sensitivity analysis to address uncertainty surrounding 
the value of parameter inputs, etc.) were extracted. 
 
Quality Assessment 
The quality of reporting by the economic evaluations was assessed using the Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) checklist [19]. The quality of 
each economic evaluation was scored using CHEERS criteria, which allows overall scores 
from 0 to 24 (24 representing the best score possible). In addition, the methodological quality 
of any randomised controlled trial underpinning an economic evaluation was assessed using 
the Cochrane Collaboration’s risk of bias tool [20]. The risk of bias domains included random 
sequence generation, allocation concealment, blinding of participants, blinding of personnel, 
blinding of outcome assessment, incomplete outcome data and selective outcome reporting. 
Each domain was classified as of low, high or unclear risk [20]. Where studies failed to report 
an item, it was classified as unclear. 
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Analysis 
Cost data extracted from studies were inflated, where necessary, to 2016 prices using the 
relevant country-specific Gross Domestic Product (GDP) deflator index, and subsequently 
converted, where necessary, from their respective currencies into US dollars using purchasing 
power parities supplied by the Organisation for Economic Co-operation and Development 
(OECD) [21]. For studies that failed to report their currency price dates, it was assumed that 
the costs used in the valuation process applied to the financial year prior to the publication of 
the study. 
      
Methodological variations between studies, including variations in underpinning health care 
practices across jurisdictions and variations in the relative prices of labour and capital inputs 
across jurisdictions, prevented a pooling of economic data akin to meta-analyses performed 
on clinical effectiveness estimates. Rather, cost-effectiveness estimates and broader economic 
outcomes are presented in a descriptive manner according to broad economic design. 
 
RESULTS 
 
Search results  
In total, 14,636 records were identified from the bibliographic searches. After removing 
6,853 duplicates, 7,783 titles and abstracts were reviewed and 7,773 articles were 
subsequently excluded at the title and abstract screening stage (Figure 1). Common reasons 
for exclusion were that the studies were not economic evaluations, the population did not 
include breast cancer patients, or the intervention was not exercise or physiotherapy based. 
Ten articles fulfilled screening criteria and were retrieved for full-text analysis; of these, 
seven fulfilled the study inclusion criteria. Two studies were excluded at the full report stage 
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because they were not economic evaluations [22,23], whilst a third study by Kampschoff and 
colleagues [24] presented only aggregated results across breast and colon cancer patients and 
it was not possible to obtain data only for breast cancer (Figure 1). Of the seven included 
studies, one study by Perrier and colleagues [25] was reported as a conference poster and 
further details were obtained directly from the authors. 
 
Study characteristics  
Descriptive information (study design, patient characteristics, interventions, outcomes) 
pertaining to each included study is presented in Table 1. Classified by country of origin, 
three studies were conducted in the Netherlands, three conducted in Australia and one in 
France. Five studies carried out trial-based economic evaluations [13,25-28], whereas two 
studies conducted economic evaluation based on decision models [12,29]. A decision model 
theoretically allows for the extrapolation of costs and effects beyond the time horizon of trial 
data, can reflect all appropriate evidence, can compare all relevant options, and can make 
head-to-head comparisons of alternative competing interventions when relevant trials do not 
exist [30,31]. The study by Gordon et al [12] made head-to-head comparisons of alternative 
competing interventions without trial-based data, whereas Mewes et al [29] used decision 
modelling to extrapolate costs and effects beyond the time horizon of the trial data used [32].  
 
Interventions and outcomes  
The type of physiotherapy and exercise interventions evaluated by the studies included home-
based self-managed exercises [13,28,29], home-based self-managed and supervised 
physiotherapy [12], home-based supervised exercises with different delivery methods (face-
to-face or over-the-telephone) [26], and group-based supervised exercise programmes 
[12,25,27,28]. The physiotherapy and exercise interventions targeted a range of health and 
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fitness goals including strength and flexibility, balance, endurance and overall fitness (Table 
1).  The range of control interventions included usual care [12,26,27,29], a sham intervention 
(active control of flexibility and relaxation activities) [13], dietary advice [25], and usual care 
with no routine exercise [28]. For the five studies using trial data , the primary outcome 
measures included the self-report Functional Assessment of Cancer Therapy - Breast Cancer 
version 4 (FACT-B+4) [26], EuroQol 5-dimension questionnaire 3 level (EQ-5D-3L) [13], 
European Organisation for Research and Treatment of Cancer core quality of life 
questionnaire (EORTC QLC-C30) [13], cardiorespiratory fitness [28], and the 
Multidimensional Fatigue Inventory (MFI) and Fatigue Quality List (FQI) [27].  
 
Economic evaluations  
Information relating to the characteristics and economic outcomes of the economic 
evaluations is presented in Table 2. All economic evaluations were published between 2005 
and 2018. One study was a cost-effectiveness analysis (CEA) [25], three were stand-alone 
cost–utility analyses (CUAs) [13,27,29] and three were combined CEAs and CUAs 
[12,26,28]. Four studies adopted a societal perspective [12,13,27,28], whilst one adopted a 
health care system perspective [29], one a private and service provider perspective [26], and 
one a national insurance perspective [25]. The mean total costs per patient for delivering 
group exercise interventions ranged from AUS$342 (US$327, 2016 prices) for a home-based 
physiotherapy intervention [12] to €31,133 (US$38,819, 2016 prices) for a home-based, low-
intensity, individualised, self-managed physical activity programme with the addition of 
behavioural reinforcement [28]. The primary measure(s) of health consequence included in 
the seven economic evaluations fell into the following categories: number of rehabilitated 
cases and quality adjusted life years (QALYs) [12,26]; change in body mass index (BMI) and 
cardiorespiratory fitness [25]; fatigue and QALYs [28]; and QALYs alone [13,27,29]. 
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QALYS were derived from the EQ-5D-3L measure in four studies [13,26-28], whilst in one 
study [12], QALYs were generated by multiplying period of life by utility scores obtained 
using a single-item linear analogue scale entitled the Subjective Health Estimation (SHE) 
scale which had been developed and validated by the International Breast Cancer Study 
Group [33]. A further study used a mapping algorithm to estimate EQ-5D utility scores from 
the short-form six dimension health index (SF-6D) and then used those values to calculate 
QALYs [29]. 
 
Quality of studies  
The methodological quality assessment of the economic evaluations as judged by the 
CHEERS checklist produced scores ranging from 19 to 22 (Online Resource 2). For risk of 
bias, although there were five studies that carried out trial-based economic evaluations 
[13,25-28], Mewes et al [29] used a decision model that drew upon data from a trial [32];  
therefore, risk of bias results are presented for six studies. The methodological assessment of 
risk of bias was consistent across studies (Figure 2, Online Resource 3) with the majority of 
studies considered at low of risk of bias for the majority of domains. However, all studies 
were considered at high risk of bias for the domain “blinding of participants and personnel” 
due to the unconcealed nature of the exercise and physiotherapy interventions.  
 
Summary of results of economic evaluations 
 
The results pertaining to the cost-effectiveness of the exercise and physiotherapy 
interventions for breast cancer patients evaluated are summarised in Table 2. 
 
Cost-effectiveness studies  
12 
 
Only one economic evaluation, a study conducted in France, reported non-QALY based 
results alone and found that a supervised group-based intervention dominated usual care (i.e. 
generated improved health outcomes and lower overall costs, on average) with a negative 
ICER of €-11,159 per decline in BMI unit [25]. The results for cardiorespiratory fitness also 
showed that the intervention dominated usual care with a negative ICER of €-6,030 per 
estimated aerobic capacity unit gained for VO2max [25]. Probabilistic sensitivity analyses 
conducted by the authors showed that the probability that the intervention is cost-effective 
reached 56% based on the BMI outcome and 69% based on the VO2max outcome [25]. 
 
Cost-utility studies 
Three economic evaluations estimated cost-effectiveness results using the QALY framework 
alone [13,27,29]. One Australian study reported that a home-based self-managed exercise 
intervention was not cost-effective, with only a 5% probability that it was both less costly and 
more effective than the control [13]. The second study, from the Netherlands, found that a 
supervised group-based exercise intervention was not cost-effective compared with usual care 
with an ICER of €291,200 per QALY gained (US$375,572, 2016 prices) [27]. Scenario 
analysis, where the cost-effectiveness was considered from a healthcare perspective, provided 
similar to results of the baseline analysis [27]. The third study, also from the Netherlands, 
found that a home-based self-managed exercise intervention generated an ICER of €28,078 
(US$35,707, 2016 prices) per QALY gained and the authors concluded that this was 
borderline cost-effective because the ICER of €28,078 fell below recommended cost-
effectiveness thresholds [29]. Sensitivity analyses found that the outcomes were influenced 
by, first, utility values for the “menopausal symptoms” and “reduction in menopausal 
symptoms” health states and, second, the duration of the treatment effect, with shorter effect 
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duration resulting in lower cost-effectiveness. The outcomes of this study were most sensitive 
to a reduction of the duration of the treatment effect from 5 to 3 and 1.5 years [29]. 
 
 
Combined cost-effectiveness and cost-utility studies 
Three studies estimated cost-effectiveness results using both QALY and non-QALY 
frameworks. An Australian study showed that a home-based self-managed and supervised 
physiotherapy intervention (ICER: AUS$ 1,344 (US$1,284) per QALY, 2016 prices) and a 
supervised group-based exercise and psychosocial intervention (ICER: AUS$ 14,478 
(US$13,831) per QALY, 2016 prices) were both more effective than usual care, with the 
home-based intervention being the more cost-effective of the two experimental interventions 
[12]. In contrast, the results based on rehabilitated cases showed that usual care was less 
costly and more effective than both the home-based physiotherapy and group-based exercise 
and psychosocial interventions [12]. The ICERs for the two experimental interventions 
remained robust to several sensitivity analyses, with the exception of variations in utility 
scores to the lower limits of confidence intervals when QALYs were the outcome used. The 
authors conducted post-hoc analyses to check whether self-reported function (FACT-B+4) 
(used to estimate rehabilitated cases) and health utility scores (derived from Subjective 
Health Estimation scale) measured different concepts; they found that the measures were only 
modestly correlated (coefficient = 0.54, p < 0.001), which signified that the two outcome 
measures were sufficiently different and therefore different cost-effectiveness conclusions 
were possible given the study design [12]. 
 
Another Australian study reported that a home-based supervised exercise intervention was 
not cost-effective from either a health service provider (ICER: AUS$ 105,231 (US$73,786) 
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per QALY, 2016 prices) or a private payer perspective (ICER: AUS$ 90,842 (US$63,697) 
per QALY, 2016 prices) [26]. In contrast, the authors reported that results based on 
rehabilitated cases showed that the home-based supervised exercise intervention was cost-
effective, with an ICER of approximately AUS$2,400 (US$1,677, 2016 prices) per improver 
[26]. Sensitivity analyses indicated that the incremental cost-effectiveness ratios using 
QALYs gained were most sensitive to variations in EQ-5D-3L utility values within 95% 
confidence limits. Other variations in variables tested produced negligible changes to the 
incremental cost-effectiveness ratios. The likelihood of the service provider model being 
cost-effective was 44.4%, and 46.3% for the private model, at a cost-effectiveness threshold 
of AUS$50,000 per QALY gain. The authors concluded that whilst QALYs are the preferred 
measure of health consequence in health economic evaluations, there are a couple of reasons 
why they may not have been appropriate for this clinical context. Firstly, the intervention 
duration was not expected to extend participant survival during the trial period. Secondly, the 
mean health utility weight for the study participants (0.84) was similar to that reported for the 
Australian general population. Therefore, detecting differences in QALYs was deemed 
unrealistic in their sample [26].  
 
A third study, conducted in the Netherlands, reported that a supervised exercise intervention 
was borderline cost-effective compared to usual care with an ICER of €26,916 (US$33,561, 
2016 prices) per QALY gained [28]. The authors report that the non-QALY based results for 
this intervention suggest that it is cost-effective in terms of cost per unit change in general 
fatigue (ICER of €788), and cost per unit change in physical fatigue (ICER of €1,402) [28]. 
The same study showed that a home-based self-managed exercise with the addition of 
behavioural reinforcement was not cost-effective compared with usual care with an ICER of 
€70,052 (US$87,347, 2016 prices) per QALY gained [28]. In contrast, the authors reported 
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that home-based self-managed exercise with the addition of behavioural reinforcement is 
cost-effective in terms of cost per unit change in general fatigue (ICER of €4,711), and cost 
per unit change in physical fatigue (ICER of €10,384) [28]. Scenario analyses conducted by 
the authors found that the probability of cost-effectiveness for both comparators was greater 
among compliant participants [28]. 
 
 
DISCUSSION 
 
Evidence on the cost-effectiveness of exercise and physiotherapy interventions for the 
treatment of breast cancer was systematically assessed in this review. We identified only 
seven studies reporting on the cost-effectiveness of exercise and physiotherapy interventions 
for breast cancer patients [12,13,25-29], which between them evaluated nine different 
exercise-based interventions. These studies were generally of high quality and at low risk of 
bias. There have been two previous reviews that have reported evidence on the cost-
effectiveness of exercise-based interventions in the treatment of breast cancer. The first 
review by Roine et al 2009 [11] identified a single study, which reported that a home-based 
self-managed physiotherapy intervention and a supervised group-based exercise intervention 
with psychosocial support were more cost-effective than usual care [12]; this study is 
included in our review. The second review by Mewes et al 2012 [10] also only identified a 
single study, which concluded that a home-based self-managed exercise intervention was not 
cost-effective compared to an active control consisting of flexibility and relaxation activities 
after breast cancer surgery [13]; this study is also included in our review. 
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Using QALYs as the primary measure of health consequence, the evidence surrounding the 
cost-effectiveness of exercise and physiotherapy interventions for breast cancer rehabilitation 
following surgery was equivocal. Three studies reported favourable cost-effectiveness results 
for different exercise or physiotherapy interventions [12,28,29]. In contrast, four studies 
conducted in different patient populations and healthcare settings found that exercise or 
physiotherapy interventions were not cost-effective using the QALY framework and on the 
basis of recommended country-specific cost-effectiveness thresholds for the QALY metric 
[13,26-28].  
 
Cost-effectiveness evidence was only reported within three countries, each with different 
healthcare systems (Australia, The Netherlands and France). This cost-effectiveness evidence 
was largely based on small studies with sample sizes ranging from 60 to 244 women. 
Methodological variations in recommended approaches across jurisdictions to the conduct of 
health economic evaluations may partly explain variations in cost-effectiveness results. For 
example, not all studies using the QALY framework for the analyses estimated QALYs using 
the same multi-attribute utility measure. The EQ-5D-3L was used in four studies [13,26-28], 
whilst one study used utilities derived from the SHE [12] and a further study relied upon an 
external mapping algorithm [29]. Furthermore, variations in the content and delivery of 
exercise and physiotherapy interventions and the relative prices of the resource components 
of those interventions and their resource consequences are also likely to be factors driving the 
lack of consistency in findings. Consequently, any variation in cost-effectiveness estimates is 
likely to be driven, at least in part, by variations in methodological factors, as well as 
variations in the essential features of the interventions evaluated.  
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The comparators considered by the studies included in this systematic review can broadly be 
categorised as post-operative exercise versus control [12,26], exercise versus control during 
adjuvant breast cancer treatment [13,25,27,28], and exercise versus control following breast 
cancer treatment [29]. We found no economic evaluations comparing post-operative early 
versus delayed exercise interventions despite evidence for their clinical effectiveness [8]. 
Clearly, there is a need for further research that assesses the cost-effectiveness of the broad 
range of exercise and physiotherapy interventions that have been developed, many of which 
are used in routine clinical practice. A particular focus of future research should be to 
disentangle the contributing effects of frequency, intensity, time and type of exercise and 
physiotherapy interventions on cost-effectiveness outcomes with the view to specifying the 
relationship between features of those interventions and cost-effectiveness outcomes. 
Furthermore, although all but one study included in this systematic review measured health 
consequences in terms of QALYs, which are widely recommended for cost-effectiveness 
based decision-making, there is a need for assessments of the sensitivity of widely used 
multi-attribute utility measures such as the EQ-5D-3L to changes in outcomes of interest, 
such as symptoms of fatigue [8]. 
 
The key strength of this study is the robust methodology adopted, which included following 
recommended guidelines for the conduct of systematic reviews of economic evaluations [18], 
and a transparent approach to study identification, assessment, data extraction and critical 
appraisal. Variations in methodological approaches and factors precluded the use of meta-
analysis for combining cost-effectiveness evidence across studies, in line with other 
systematic reviews of economic evaluations [34,35]. The study does have limitations, which 
should be borne in mind by readers. First, we did not search grey literature databases, 
including TRIP and Open Grey, within our search strategies. We worked closely with an 
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information specialist to develop, test and refine our search strategies, but cannot preclude the 
possibility of exclusion of potentially relevant studies. Second, interpretation of the cost-
effectiveness assessments that measured health consequences in terms of natural or 
biomedical units of outcomes, such as changes in BMI or cardiorespiratory fitness [25], is 
constrained by absence of external cost-effectiveness thresholds for these health 
consequences. External evidence from stated or revealed preference studies on the value that 
should be placed on these effects will be required for the purposes of cost-effectiveness based 
decision-making. 
 
 
CONCLUSION 
 
This review has highlighted that the evidence base surrounding the cost-effectiveness of 
exercise and physiotherapy interventions for the treatment of breast cancer remains sparse 
with contrasting conclusions. Future research should particularly aim to broaden the evidence 
base by disentangling the contributing effects of frequency, intensity, time and type of 
exercise and physiotherapy interventions on cost-effectiveness outcomes. 
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Table 1: Description of methods of included economic evaluations 
 
Authors 
(Country) 
Gordon et al [12] 
(Australia) 
Gordon et al [26] 
(Australia) 
Haines et al [13] 
(Australia) 
May et al [27] 
(The Netherlands) 
Mewes et al [29] 
(The Netherlands) 
Perrier et al [25] 
(France) 
Van Waart et al [28] 
(The Netherlands) 
Year 2005 2017 2010 2017 2013 2016 2018 
Study design Model based economic 
evaluation  
 
Study design is 
observational for both 
DAART and 
STRETCH 
RCT with 
economic 
evaluation 
RCT with economic 
evaluation 
RCT with economic 
evaluation 
Model based economic 
evaluation 
 
Hypothetical cohort of 
1,000 
 
RCT with 
economic 
evaluation 
RCT with economic 
evaluation 
Period of intervention STRETCH – 8 weeks, 
up to 12 months follow-
up 
 
DART – 6 weeks, up to 
12 months follow-up 
8 months, up to 
12 months follow-
up 
6 months, up to 12 
months follow-up 
18 weeks, up to 9 
months follow-up 
12 weeks, up to 6 months 
follow-up 
6 months 1-4 months, 6 
months follow-up 
Analytic horizon 12 months 12 months 6 months 9 months 5 years 6 months Less than 12 months 
Setting Community Hospital and 
community 
Hospital and 
community 
Outpatient clinics  Community Community 
Population Women with breast 
cancer, aged 25-74 
Women with 
breast cancer aged 
20-69, resident in 
Brisbane area 
Women with newly 
diagnosed breast 
cancer undergoing 
adjuvant therapy 
Histological diagnosis 
of breast cancer <6 
weeks pre- 
recruitment; stage 
M0; scheduled for 
chemotherapy; Age 
25–75 years; no 
cancer treatment in 5 
years preceding 
recruitment. 
Female breast cancer 
patients; aged < 50 years, 
premenopausal, had 
undergone adjuvant 
chemotherapy and/or 
hormonal therapy, had 
experienced a treatment-
induced menopause, and 
who reported at least a 
minimal level of 
menopausal symptoms. 
 
Breast cancer 
patients receiving 
first-line adjuvant 
chemotherapy 
Patients scheduled 
for adjuvant 
chemotherapy for 
breast cancer at one 
of 12 participating 
hospitals in wider 
Amsterdam region of 
the Netherlands 
between 2010 and 
2012. 
Sample Size Study Group DAART n=36 
STRETCH n=31 
Treatment n=134 Intervention n=46 
 
Intervention n=87  Intervention 
(n=41) 
OnTrack (n=76) 
Onco-Move (n=77) 
Control group Usual care (n=208) Usual care n=60 Control n=43 Control n=78  Control (n=19) Control (n=77) 
Age, Mean (SD)             DAART 59 (10.7)  
STRETCH 54 (11.3) 
Usual care 55 (10.3) 
52 (8) 
 
Intervention 55.9 
(10.5) 
Control 54.2 (11.5) 
Intervention 50.0 
(7.9) 
Control 49.4 (7.6) 
Age < 50 years 
 
18-75 years OnTrack 49.9 (8.4) 
 
Onco-Move 50.5 
(10.1) 
Usual Care 51.6 (8.8) 
Intervention DAART - early home-
based physiotherapy 
intervention. Main 
8-month exercise 
program for 
women after 
Participants 
received a 
multimedia 
Supervised 1-hour 
aerobic and resistance 
exercise (twice per 
Physical exercise 
intervention consisting of 
a 12-week home-based 
6-month 
supervised 
physical activity 
OnTrack: moderate-
to-high intensity, 
combined resistance 
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components: Recovery 
of shoulder range of 
movement (SROM), 
Education, Tailored 
exercise prescription for 
self-management. 
 
STRETCH - a group-
based exercise and 
psychosocial 
intervention. Main 
components: Recovery 
of SROM, Education, 
Discussion of 
psychosocial issues. 
surgery for 
primary breast 
cancer. 
Intervention 
delivered through 
either face‐ to‐
face home 
delivery or by 
telephone over an 
8‐ month period 
starting 6 weeks 
after breast 
surgery. The 
intervention 
involved 16 
scheduled 
sessions. 
 
instructional 
package with 
equipment. A 
program combining 
a range of exercise 
approaches, with 
balance and 
shoulder mobility 
components.  
Included 
progression. 
week for 18 weeks). 
The programme was 
individualised to the 
patient’s personal 
preferences and 
fitness level. The 1-
hour exercise classes 
included a warming 
up (5 min), aerobic 
and muscle strength 
training (50 min) and 
a cooling down 
(5min). 
Recommended to be 
physically active for 
at least 30min a day 
on at least three other 
days. 
exercise program, 
individually tailored 
during an intake session 
with a physiotherapist. 
program of indoor 
and outdoor group 
sessions in 
addition to usual 
dietary advice. 
 
and aerobic exercise 
program, supervised 
by specially trained 
physiotherapists. 
Twice a week, six 
large muscle groups 
are trained, followed 
by 30 min of aerobic 
exercises. 
 
Onco-Move: home-
based, low-intensity, 
individualised, self-
managed physical 
activity program, 
with the addition of 
behavioural 
reinforcement. 
Specially trained 
nurses encourage 
participants at each 
chemotherapy cycle 
to engage in 30 min 
of physical activity 
per day, 5 days a 
week 
Control Usual care a 
population-based 
sample, representative 
of women with breast 
cancer in the same 
geographic area. 
Usual care group 
received no 
regular or formal 
advice outside of 
routine health care 
contacts. 
Active (sham 
intervention) control 
of flexibility and 
relaxation activities.  
Video & supporting 
material looked but 
actual exercises 
described differed. 
No progression.  
Usual care - maintain 
habitual physical 
activity pattern up to 
week 18. Thereafter, 
offered routine 
exercise programmes 
after cancer treatment. 
 
usual care, waiting list 
control 
Dietary advice 
only. 
Varied according to 
hospital guidelines 
and preferences but 
did not involve 
routine exercise. 
Primary health outcome of the 
study 
DAART study 
outcomes: shoulder 
ROM, arm 
circumference, 
function, pain,  
 
STRETCH: shoulder 
ROM 
QoL – FACT B+4 HRQoL – EQ-5D, 
EORTC C30 
Fatigue - MFI Endocrine symptoms – 
FACT-ES 
Adherence to the 
intervention 
 
Cardiorespiratory 
fitness – endurance 
and heart rate at the 
end of an 
incremental bicycle 
ergometer test. 
DAART: Domiciliary Allied Health and Acute Care Rehabilitation Team, EORTC C30: European Organisation for Research and Treatment of Cancer Core questionnaire, EQ-5D: Euro Qol 5 dimensions, FACT-
B +4: Functional Assessment of Cancer Therapy-Breast, FACT-ES: Functional Assessment of Cancer Therapy Questionnaire Endocrine Scale, MFI: Multidimensional Fatigue Inventory and Fatigue Quality List, 
NA: Not applicable, QoL: Quality of Life, RCT: Randomised control trial, STRETCH: Strength Through Recreation Exercise Togetherness Care Health, SROM: Shoulder Range of Movement. 
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Table 2. Outcomes of included economic evaluations 
Authors 
(Country) 
Gordon et al [12] 
(Australia) 
Gordon et al [26] 
(Australia) 
Haines et al [13] 
(Australia) 
May et al [27] 
(The Netherlands) 
Mewes et al [29] 
(The Netherlands) 
Perrier et al [25] 
(France) 
Van Waart et al [28] 
(The Netherlands) 
Type of study CEA & CUA, 
Model based, 
Markov model 
12 months 
CEA & CUA 
 
Trial based 
CUA 
 
Trial based 
CUA 
 
Trial based 
CUA 
Model based 
 
Markov model 
5 years 
CEA 
 
Trial based 
CEA & CUA 
 
Trial based 
Perspective Societal Service provider, private Societal Societal healthcare system 
perspective 
French national 
insurance perspective 
Societal 
Costs 
(Currency, price 
date, types of costs, 
sources of cost 
data, valuation of 
costs. discount 
rate) 
2004 AUS $, 
Direct and indirect, 
Literature, national tariffs 
No discounting 
 
Average cost 
DAART  AUS $342 
STRETCH  AUS $1,038 
Usual Care (UC)  AUS $189 
 
Incremental cost vs UC 
DAART  AUS $133 
STRETCH  AUS $941 
2014 AUS $, 
Intervention, out of pocket, 
Trial records, invoices 
No discounting 
 
Mean costs 
Service provider  AUS $967 
Private  AUS $838 
Usual care  AUS $20 
 
2006 AUS $, 
Intervention, Direct 
health and 
productivity 
Trial data, Market 
prices, Australian 
DRG cost weights, 
mean wage rates 
No discounting 
 
Total costs Median 
(IQR), mean 
 
Intervention AUS 
$3864 (2450, 
10076), 10082 
 
Control AUS $3594 
(2316, 7992), 3819 
2011 Euros €, 
Direct and indirect, 
Trial data, 
own cost price 
calculations, 
No discounting 
 
 
Total societal costs, 
Mean (SD) 
Intervention €25,105 
(10,403) 
Control €22,215 
(8,652) 
2011 Euros €, 
Intervention costs, 
Health care costs, 
Medication, 
Literature, national 
tariffs 
Discount rate 4% 
 
 
Total cost 
Intervention €2,983 
Control €2,798 
2012 Euros €, 
Intervention, total, 
Trial records, 
No discounting 
 
Total costs, mean 
(SD) 
Intervention €15,776 
(9,772) 
Control €18,475 
(14,612) 
2017 Euros €, 
Intervention, Direct 
Health care, 
Absenteeism, Unpaid 
productivity 
Trial data, National 
tariffs 
No discounting 
 
Total costs, mean (SE) 
OnTrack €29,589 
(1,615) 
OncoMove €31,133 
(2,236) 
Usual Care €28,714 
(1,984) 
Effects 
(type of effects, 
sources of QALYs, 
discount rate) 
Rehabilitated cases n (%) 
QALYs (Subjective Health 
Estimation (SHE) scale) 
No discounting 
 
Rehabilitated cases n (%) 
DAART 14 (45%) 
STRETCH 12 (48%) 
Usual care 99 (52%) 
 
Utility score, mean (SD) 
DAART 0.77 (0.19) 
STRETCH 0.79 (0.18) 
Usual care 0.73 (0.17) 
Rehabilitated cases 
QALYs (EQ‐ 5D‐ 3L) 
No discounting 
 
Improvers 
Intervention 69 
Usual care 21 
 
Mean QALY’s 
Intervention 0.846 
Usual care 0.837 
Utility scores (EQ‐
5D‐ 3L) 
No discounting 
 
 
Utility score, mean 
(SD) 
 
Intervention 0.80 
(0.21) 
Control 0.83 (0.18) 
QALYs (EQ‐ 5D‐
3L) 
No discounting 
 
QALYS total, mean 
(SD) 
Intervention 0.569 
(0.03) 
Control 0.560 (0.04) 
QALYs (EQ-5D 
derived/mapped from 
SF-6D) 
Discount rate 1.5% 
 
Total QALYs 
Intervention 4.399 
Control 4.392 
 
Change in BMI score 
VO2max gained 
No discounting 
 
Change in BMI score 
Intervention 0.05 
Control 0.29 
 
Change in VO2max 
Intervention 0.39 
Control -0.06 
QALYs (EQ-5D-3L) 
General fatigue 
Physical fatigue 
No discounting 
 
 
QALYs gained, mean 
(SE) 
OnTrack 0.65 (0.01) 
OncoMove 0.63 (0.02) 
Usual Care 0.58 (0.02) 
Outcomes Incremental cost per rehab case 
DAART Dominated by UC 
STRETCH Dominated by UC 
ICER improvers 
Service provider  AUS $ 
2,644 
Only 5% probability 
that the intervention 
would be both less 
Incremental costs 
€2,912 
Incremental costs 
€185 
ICERS 
€-11,159 per BMI 
unit lost 
Incremental cost 
OnTrack vs UC 1,184 
OncoMove vs UC 2,571 
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ICER QALYs 
DAART vs UC  AUS $1,344 
STRETCH vs UC  AUS 
$14,478 
Private  AUS $ 2,282 
 
ICER QALYS’s 
Service provider  AUS 
$105,231 
Private  AUS $90,842 
costly and more 
effective than the 
control. 
Incremental QALYs 
0.01 
 
ICER was €291,200 
Incremental QALYs 
0.0067 
 
ICER €28,078 
€-6,030 per estimated 
aerobic capacity unit 
gained for VO2max 
 
Intervention 
dominates usual care 
 
Incremental QALYs 
OnTrack vs UC 0.04 
OncoMove vs UC 0.04 
 
ICERs 
 
Improvement in general 
fatigue 
OnTrack vs UC 788 
OncoMove vs UC 4,711 
 
Improvement in 
physical fatigue 
OnTrack vs UC 1,402 
OncoMove vs UC 
10,384 
 
QALYs 
OnTrack vs UC 26,916 
OncoMove vs UC 
70,052 
Sensitivity 
analyses conducted 
A one-way sensitivity analysis 
was performed for several cost 
and outcome estimates.  
 
PSA of cost-effectiveness 
inputs 
 
One-way sensitivity of 
QALYs and costs. 
 
PSA of cost-effectiveness 
inputs 
None Scenario analysis – 
Cost-effectiveness 
from healthcare 
perspective 
 
One-way sensitivity 
PSA 
PSA Scenario analysis 
 
Results of 
sensitivity analyses  
The ICERs for the STRETCH 
and DAART interventions 
remained robust to nearly all 
sensitivity analysis, with the 
exception of varying utility 
scores to their lower confidence 
limits when QALYs were the 
outcome used. 
Sensitivity analyses 
indicated that the 
incremental cost‐
effectiveness ratios using 
QALYs gained were most 
sensitive when the EQ‐5D-
3L utility values were 
varied within their 95% 
confidence limits.  Other 
variations in variables 
tested (e.g., leasing costs) 
produced negligible 
changes to the incremental 
cost-effectiveness ratios. 
The likelihood of the 
service provider model 
being cost-effective was 
44.4%, and 46.3% for the 
NA Similar to results of 
the baseline analysis 
The outcomes were 
most influenced by: 
(1) the utility values 
of the “menopausal 
symptoms” and 
“reduction in 
menopausal 
symptoms” health 
states, and (2) the 
duration of the 
treatment effect, with 
shorter effect duration 
resulting in lower 
cost-effectiveness. 
 
The outcomes of this 
study were most 
sensitive to a 
Probability that 
intervention is cost-
effective reached 
56% for the BMI 
outcome measure and 
69% for the VO2max 
outcome measure. 
The probability of cost-
effectiveness for both 
comparators was greater 
among compliant 
participants. 
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private model, at a cost-
effectiveness threshold of 
AUS$50 000 per QALY 
gained. 
reduction of the 
duration of the 
treatment effect from 
5 to 3 and 1.5 years 
Conclusion Rehabilitated cases - not cost-
effective when rehabilitated 
cases were used as the outcome 
for generating the ICER, the 
usual care group was superior to 
both STRETCH and DAART 
interventions. 
 
When QALYs were used, the 
DAART group was more 
effective than both STRETCH 
and usual care. 
In this study, the EQ‐ 5D‐
3L was not sensitive to 
capture the intervention 
effect, and therefore, 
QALYs were not entirely 
appropriate for this context. 
 
In terms of the numbers of 
women reporting clinically 
significant improvements in 
quality of life, the 
intervention, using either 
service model, may be 
cost‐ effective at 
approximately A$2400 per 
improver (or A$300 per 
month). 
Not cost-effective 
 
Provision of 
multimodal exercise 
programs will 
improve the short-
term health of 
women undergoing 
adjuvant therapy for 
breast cancer but are 
of questionable 
economic 
efficiency. 
Not cost-effective 
 
Probability that the 
intervention would be 
cost-effective at 
20,000 threshold is 
2%. 
Physical Exercise is a 
cost-effective strategy 
for alleviating 
treatment-induced 
menopausal 
symptoms in this 
population 
On the basis of both 
cost and 
effectiveness, the 
study finds potential 
advantages in using 
6-month supervised 
physical activity 
program in addition 
to the usual dietetic 
care instead of one 
dietetic care only. 
Onco-Move is not likely 
to be cost-effective. 
 
Depending on the 
decision-makers’ 
willingness-to-pay, 
OnTrack could be 
considered cost-
effective in comparison 
with UC.   
 
Both interventions had a 
low probability of being 
cost-effective for 
physical fitness 
 
Quality score1 22 20 20 20 22 19  
CEA: cost-effectiveness analyses, CI: confidence interval, CUA: cost-utility analyses, DAART: Domiciliary Allied Health and Acute Care Rehabilitation Team, DRG: Diagnosis Related Grouping, EQ-5D-3L: 
EuroQol generic health questionnaire 3 level version, ICER: incremental cost-effectiveness ratio, IQR: inter quartile range, PSA: Probabilistic sensitivity analyses, QALYs: Quality adjusted life-years, SD: standard 
deviation, SE: standard error, STRETCH: Strength Through Recreation Exercise Togetherness Care Health. 
1 Quality assessment based on the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement[36] 
  
